Management of diabetes mellitus in patients undergoing liver transplantation

Abstract

Diabetes is a common feature in cirrhotic individuals both before and after liver transplantation and negatively affects prognosis. Certain aetiological agents of chronic liver disease and loss of liver function per se favour the occurrence of pre-transplant diabetes in susceptible individuals, whereas immunosuppressant treatment, changes in lifestyle habits, and donor- and procedure-related factors contribute to diabetes development/persistence after transplantation. Challenges in the management of pre-transplant diabetes include the profound nutritional alterations characterizing cirrhotic individuals and the limitations to the use of drugs with liver metabolism. Special issues in the management of post-transplant diabetes include the diabetogenic potential of immunosuppressant drugs and the increased cardiovascular risk characterizing solid organ transplant survivors. Overall, the pharmacological management of cirrhotic patients undergoing liver transplantation is complicated by the lack of specific guidelines reflecting the paucity of data on the impact of glycaemic control and the safety and efficacy of anti-hyperglycaemic agents in these individuals.

Keywords: Acarbose (PubChem CID: 444254); Anti-hyperglycaemic drugs; Canagliflozin (PubChem CID: 24812758); Dapagliflozin (PubChem CID: 9887712); Diabetes mellitus; Empagliflozin (PubChem CID: 11949646); Exenatide (PubChem CID: 45588096); Immunosuppressant drugs; Lifestyle intervention; Linagliptin (PubChem CID: 10096344); Liraglutide (PubChem CID: 16134956); Liver transplantation; Metformin (PubChem CID: 4091); Pioglitazone (PubChem CID: 4829); Sitagliptin (PubChem CID: 4369359).